

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims. Additions are indicated by underlining and deletions are indicated by strikeouts and/or double bracketing.

1. (Currently Amended) An amorphous form of olanzapine on a commercial scale, wherein the olanzapine comprises less than 10% of crystalline forms of olanzapine and less than 2% of other impurities, and wherein the olanzapine is for use in therapy by oral or parenteral administration ~~preparable by a process comprising the step of melting one or more crystalline forms of olanzapine.~~
2. (Original) An amorphous form of olanzapine as claimed in claim 1, wherein the olanzapine is in particulate form.
3. (Previously Presented) An amorphous form of olanzapine as claimed in claim 1, wherein the olanzapine is substantially pure.
4. (Previously Presented) An amorphous form of olanzapine as claimed in claim 1, having an IR spectrum substantially as shown in Figure One, an XRPD spectrum substantially as shown in Figure Two, and/or a DSC trace substantially as shown in Figure Three.
5. (Cancelled)
6. (Previously Presented) A process for the preparation of an amorphous form of olanzapine comprising the step of melting one or more crystalline forms of olanzapine.
7. (Original) A process as claimed in claim 6, further comprising the step of cooling the melt.

8-11. (Cancelled)

12. (Previously Presented) A method of preparing a pharmaceutical composition, comprising utilizing an amorphous form of olanzapine as claimed in claim 1.
13. (Original) A method as claimed in claim 12, wherein the pharmaceutical composition is for oral or parenteral administration.
14. (Previously Presented) A method as claimed in claim 12, wherein the pharmaceutical composition is a tablet or capsule for oral administration.
15. (Previously Presented) A method as claimed in claim 12, wherein the pharmaceutical composition is a solution for oral or parenteral administration.
16. (Previously Presented) A pharmaceutical composition, comprising an amorphous form of olanzapine as claimed in claim 1.
17. (Original) A pharmaceutical composition as claimed in claim 16, further comprising a pharmaceutically acceptable carrier, excipient, or diluent.
18. (Previously Presented) A pharmaceutical composition as claimed in claim 16, wherein the composition is for oral or parenteral administration.
19. (Previously Presented) A pharmaceutical composition as claimed in claim 16, wherein the composition is in the form of a tablet or capsule for oral administration or in the form of a powder suitable for preparing a solution for oral or parenteral administration.
20. (Currently Amended) A pharmaceutical composition as claimed in claim 19, wherein the composition is in the form of a tablet or capsule and further comprises lactose,

hydroxypropylcellulose, crospovidone, microcrystalline cellulose, magnesium stearate, gelatin and/or mannitolmanitol.

21. (Original) A pharmaceutical composition as claimed in claim 19, wherein the composition is in the form of a powder and further comprises lactose, tartaric acid, hydrochloric acid and/or sodium hydroxide.
22. (Previously Presented) A pharmaceutical composition as claimed in claim 16, wherein the composition is in unit dosage form comprising from 1 mg to 30 mg amorphous olanzapine.
- 23-27. (Cancelled)
28. (Currently Amended) A method of treating a condition selected from ~~a psychiatric, psychological, or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorders~~schizophrenia, manic episode, severe manic episode, psychosis, or bipolar disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in claim 1, to a patient in need thereof.
29. (Original) A method as claimed in claim 28, wherein the patient is a human.
30. (Previously Presented) A method as claimed in claim 28, wherein the amount of an amorphous form of olanzapine administered is from 2 mg to 20 mg per day.
- 31-34. (Cancelled)
35. (Currently Amended) A method of treating a condition selected from ~~a psychiatric, psychological, or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorders~~schizophrenia, manic episode, severe manic episode, psychosis, or bipolar disorder

After Final Office Action of November 26, 2010

disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in claim 2, to a patient in need thereof.

36. (Currently Amended) A method of treating a condition selected from ~~a psychiatric, psychological, or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorders~~schizophrenia, manic episode, severe manic episode, psychosis, or bipolar disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in claim 3, to a patient in need thereof.
37. (Currently Amended) A method of treating a condition selected from ~~a psychiatric, psychological, or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorders~~schizophrenia, manic episode, severe manic episode, psychosis, or bipolar disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in claim 4, to a patient in need thereof.
38. (Currently Amended) A method of treating a condition selected from ~~a psychiatric, psychological, or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorders~~schizophrenia, manic episode, severe manic episode, psychosis, or bipolar disorder, comprising administering an effective amount of a pharmaceutical composition as claimed in claim 16, to a patient in need thereof.
39. (Previously Presented) A method of preparing a pharmaceutical composition comprising amorphous olanzapine, the method comprising the step of melting one or more crystalline forms of olanzapine.

40-42. (Cancelled)